Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

Completed · Phase 3

Conditions studied: Parkinson Disease

In brief

The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease

Key facts

Study ID

NCT00058838

Run by

Pfizer

People needed

854

Starts

2003-04-01

Expected to finish

2004-09-01

Last updated by the study team

2006-06-07

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Idiopathic Parkinson's disease < 7 years duration
• Modified Hoehn and Yahr Scale Stages I through III
• Age greater than or equal to 30 years old
• Patients or their partners must use adequate contraceptive methods
• Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures and do not plan on traveling extensively during the study

You may not qualify if…

• Atypical Parkinson's disease syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases.
• Levodopa received for 1-year accumulated interval in the last two years.
• Dopamine agonist medications or catechol-o-methyl transferase inhibitors in the 30 days prior to baseline.
• Unstable dose regimes of hypnotics, anxiolytics or antidepressants
• Dementia
• History of stereotaxic brain surgery, psychosis or active epilepsy within past year.
• Participation in clinical trial within the previous 30 days.
• Malignant melanoma or history of melanoma
• Significant medical or pshychiatric condition

Where it is running

• Pfizer Investigational Site — Tallahasse, Florida, United States
• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Huntsville, Alabama, United States
• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — Concord, California, United States
• Pfizer Investigational Site — Irvine, California, United States
• Pfizer Investigational Site — La Jolla, California, United States
• Pfizer Investigational Site — Loma Linda, California, United States
• Pfizer Investigational Site — Oceanside, California, United States
• Pfizer Investigational Site — Oxnard, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — Sunnyvale, California, United States
• Pfizer Investigational Site — Walnut Creek, California, United States
• Pfizer Investigational Site — Englewood, Colorado, United States
• Pfizer Investigational Site — Fort Collins, Colorado, United States
• Pfizer Investigational Site — Fairfield, Connecticut, United States
• Pfizer Investigational Site — Hartford, Connecticut, United States
• Pfizer Investigational Site — Fort Lauderdale, Florida, United States
• Pfizer Investigational Site — Jacksonville, Florida, United States
• Pfizer Investigational Site — Maitland, Florida, United States
• Pfizer Investigational Site — St. Petersburg, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.